Print this page
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR alpha-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The primary objective:
To evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response.
Protocol Number:
102502
Phase:
Phase II
Applicable Disease Sites:
Ovary
Drugs Involved:
CARBOPLATIN
Mirvetuximab Soravtansine
Mirvetuximab Soravtansine
Principal Investigator:
Aliza Leiser
Scope:
National
Therapies Involved:
Chemotherapy multiple agents systemic
Participating Institutions:
- RWJBarnabas Health
- Jersey City Medical Center, Jersey City
- Rutgers University
For further information about clinical trials, please contact us at 732-235-7356.